Effervescent tablet formulation for enhanced patient compliance and the therapeutic effect of risperidone

Drug Delivery

Volumn 23, Issue 1, 2016, Pages 297-306

  Mohammed, Kareem Abu Bakr ^a   Ibrahim, Howida Kamal ^a   Ghorab, Mahmoud Mohammed ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Bioavailability; dissolution; factorial design; psychiatric patients; solid dispersion

Indexed keywords

ASPARTAME; BORIC ACID; CARBOXYMETHYLCELLULOSE; DRUG SOLVENT; EUDRAGIT; EXCIPIENT; GLIDING AGENT; HALOPERIDOL; INULIN; LACTOSE; LUBRICATING AGENT; PREGELATINIZED STARCH; RISPERIDONE; STARCH; TREHALOSE; UNCLASSIFIED DRUG; NEUROLEPTIC AGENT; TABLET;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DISPERSION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG MIXTURE; DRUG SOLUBILITY; EFFERVESCENT TABLET; ELIMINATION RATE CONSTANT; EVAPORATION; FACTORIAL DESIGN; FREEZE DRYING; HYDROPHILICITY; INFRARED SPECTROSCOPY; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MEDICATION COMPLIANCE; NONHUMAN; PATIENT COMPLIANCE; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; REPRODUCIBILITY; SCALE UP; SCANNING ELECTRON MICROSCOPY; SINGLE DRUG DOSE; SOLVENT EFFECT; TABLET FORMULATION; TABLET MATRIX; TABLET PROPERTY; TASTE; THERAPY EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY POWDER DIFFRACTION; ANIMAL; DRUG FORMULATION; HALF LIFE TIME; HUMAN; MEDICINAL CHEMISTRY; PSYCHOTIC DISORDERS; RABBIT; SOLUBILITY; TABLET;

ANIMALS; ANTIPSYCHOTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG COMPOUNDING; EXCIPIENTS; HALF-LIFE; HUMANS; PATIENT COMPLIANCE; PSYCHOTIC DISORDERS; RABBITS; RISPERIDONE; SOLUBILITY; TABLETS;

EID: 84954322910     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2014.912693     Document Type: Article

References (36)

1. Bourne DWA. (2002). Pharmacokinetics. In: Banker GS, Rhodes CT, ed. Modern pharmaceutics. 4th ed. New York: Marcel Dekker Inc., 67-92.
2. Boxenbaum H. (1998). Pharmacokinetics tricks and traps: flip-flop models. J Pharm Pharm Sci 1:90-1.
3. Castelli F, Sarpietro MG, Micieli D, et al. (2008). Differential scanning calorimetry study on drug release from an inulin-based hydrogel and its interaction with a biomembrane model: pH and loading effect. Eur J Pharm Sci 35:76-85.
4. Chereson R. (1996). Bioavailability, Bioequivalence and Drug Selection. Basic Pharmacokinetics, ed. M.C. Makoid.
5. Costa P, Sousa Lobo JM. (2001). Modeling and comparison of dissolution profiles. Eur J Pharm Sci 13:123-33.
6. Damian F, Blaton N, Naesens L, et al. (2000). Physicochemical characterization of solid dispersions of the antiviral agent UC-781 with polyethylene glycol 6000 and Gelucire 44/14. Eur J Pharm Sci 10:311-22.
7. Duquesnoy C, Lacey LF, Keene ON, Bye A. (1998). Evaluation of different partial AUCs as indirect measures of rate of drug absorption in comparative pharmacokinetic studies. Eur J Pharm Sci 6:259-64.
8. El-Zein H, Riad L, El-Bary AA. (1998). Enhancement of carbamazepine dissolution: in vitro and in vivo evaluation. Int J Pharm 168: 209-20.
9. Endrenyi L, Fritsch S, Yan W. (1991). Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence. Int J Clin Pharmacol Ther Toxicol 29:394-9.
10. Ereshefsky L, Lacombe S. (1993). Pharmacological profile of risperidone. Can J Psychiatry 38:S80-8.
11. FDA. (October 6, 2006). FDA approves the first drug to treat irritability associated with autism, Risperdal. Available from: http://www.fda. gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108759. htm [last accessed 14 August 2009]
12. Hancock BC, Zografi G. (1997). Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86:1-12.
13. Harkness JE, Wagner JE. (1989). The biology and medicine of rabbits and rodents. Philadelphia: Lea and Febiger.
14. Huang ML, Van Peer A, Woestenborghs R, et al. (1993). Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 54: 257-68.
15. Jones B, Kenward MG. (2003). Design and analysis of cross-over trials (Second ed.). London: Chapman and Hall.
16. Kearney AS, Gabriel DL, Mehta SC, et al. (1994). Effect of polyvinylpyrrolidone on the crystallinity and dissolution rate of solid dispersions of the antiinflammatory CI-987. Int J Pharm 104: 169-74.
17. Khan KA. (1975). The concept of dissolution efficiency. J Pharm Pharmacol 27:48-9.
18. Khan KA, Rhodes CT. (1972). Effect of compaction pressure on the dissolution efficiency of some direct compression systems. Pharm Acta Helv 47:594-607.
19. Lacey LF, Keene ON, Duquesnoy C, Bye A. (1994). Evaluation of different indirect measures of rate of drug absorption in comparative pharmacokinetic studies. J Pharm Sci 83:212-15.
20. Lachman L, Lieberman HA, Kanig JL. (1986). The theory and practice of industrial pharmacy. Philadelphia: Lea & Febiger.
21. Lo WY, Law SL. (1996). Dissolution behavior of griseofulvin solid dispersions using polyethylene glycol, talc, and their combination as dispersion carriers. Drug Dev Ind Pharm 22:231-6.
22. Macheras P, Symillides M, Reppas C. (1993). Estimation of absorption rate constant in a one-compartment model with the profile of the bioavailable dose eliminated as a function of multiples of half-life. J Pharm Sci 82:1298-300.
23. Sweetman SC. (2009). Martindale: The complete drug reference. London: Chicago, Pharmaceutical Press, 1024-7.
24. Naima ZT. Siro T, Juan-Manuel GD, et al. (2001). Interactions between carbamazepine and polyethylene glycol (PEG) 6000: characterisations of the physical, solid dispersed and eutectic mixtures. Eur J Pharm Sci 12:395-404.
25. Olesen OV, Linnet K. (1997). Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs. J Chromatogr B Biomed Sci Appl 698:209-16.
26. Peppas NA. (1985). Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 60:110-11.
27. Rahman Z, Zidan AS, Khan MA. (2010). Risperidone solid dispersion for orally disintegrating tablet: its formulation design and nondestructive methods of evaluation. Int J Pharm 400:49-58.
28. Rowe RC, Shesky PJ, Quinn ME. (2009). Handbook of pharmaceutical excipients. Pharmaceutical Press: London.
29. Sedgwick GW, Fenton TW, et al. (1991). Effect of protein precipitating agents on the recovery of plasma free amino acids. Can J Anim Sci 71: 953-7.
30. Seltzer A, Hoffman BF. (1980). Drug compliance and the psychiatric patient. Can Fam Physician 26:725-7.
31. Skoog DA. (1998). Principles of instrumental analysis: introduction. Orlando (FL): Harcourt Brace, 18.
32. Taj R, Khan S. (2005). A study of reasons of non-compliance to psychiatric treatment. J Ayub Med Coll Abbottabad 17:26-8.
33. Thiessen JJ. (2004). Bioavailability and bioequivalence. Irvine: IUPHAR.
34. Tozer TN, Bois FY, Hauck WW, et al. (1996). Absorption rate vs. exposure: which is more useful for bioequivalence testing? Pharm Res 13:453-6.
35. Weisbroth SH, Flatt RE, Kraus AL. (1974). The biology of the laboratory rabbit. New York: Academic Press.
36. Zajc N, Obreza A, Bele M, Srcic S. (2005). Physical properties and dissolution behaviour of nifedipine/mannitol solid dispersions prepared by hot melt method. Int J Pharm 291:51-8.